A study, conducted by UC Davis Comprehensive Cancer Center researchers, shows an alarming number of California women 65 and older are facing late-stage cervical cancer diagnoses and dying from the disease, despite guidelines that recommend most women stop screening for cervical cancer at this age.
The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.
